Treatment of early-stage Hodgkin lymphoma

详细信息    查看全文

• 作者：Andreas Engert^a ; ^{a.engert@uni-koeln.de" class="auth_mail" title="E-mail the corresponding author} ; John Raemaekers^b ; ^c
• 关键词：Hodgkin lymphoma ; Early stage ; ABVD ; Positron emission tomography (PET) ; Interim PET
• 刊名：Seminars in Hematology
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：53
• 期：3
• 页码：165-170

文摘

Hodgkin lymphoma (HL) has become one of the best curable malignancies today. This is particularly true for patients with early-stage disease. Today, most patients in this risk group are treated with a combination of chemotherapy followed by small-field radiotherapy. More recent clinical trials such as the German Hodgkin Study Group (GHSG) HD10 study demonstrated, that even two cycles of ABVD followed by 20 Gy involved-field radiation therapy (IF-RT) are sufficient and result in more than 90% of patients being cured. The current treatment for early unfavorable patients is either four cycles of ABVD plus 30 Gy IF-RT or two cycles of BEACOPP_baseline followed by two cycles of ABVD plus IF-RT. Here, the European Organization for Research and Treatment of Cancer (EORTC) demonstrated that in positron emission tomography (PET)-positive patients after two cycles of ABVD, treatment switched to two cycles of BEACOPP_baseline plus radiotherapy results in significantly improved outcomes. Other aspects including attempts to further reduce intensity of treatment will be discussed.